Dupont Capital Management Corp Kinnate Biopharma Inc. Transaction History

Dupont Capital Management Corp

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Apr 27, 2022	SELL	$7.73 - $17.99 $68,054 - $158,383	-8,804 Closed	0 $0
Q4 2021 Jan 31, 2022	SELL	$16.5 - $25.48 $57,931 - $89,460	-3,511 Reduced 28.51%	8,804 $156,000
Q3 2021 Nov 03, 2021	BUY	$17.81 - $24.87 $219,330 - $306,274	12,315 New	12,315 $283,000

292K

Ticker KNTE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,145,600
Description
Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; ...

Get notified when there are updates to the investment portfolio of Dupont Capital Management Corp, based on Form 13F filings with the SEC.

Stay updated on Dupont Capital Management Corp with notifications on news.